NARCOLEPSY TYPE 1
Clinical trials for NARCOLEPSY TYPE 1 explained in plain language.
Never miss a new study
Get alerted when new NARCOLEPSY TYPE 1 trials appear
Sign up with your email to follow new studies for NARCOLEPSY TYPE 1, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New brain protein mimic could help people stay awake
Disease control Recruiting nowThis study is testing a new drug called ORX750 in people with narcolepsy or idiopathic hypersomnia—conditions that cause severe daytime sleepiness. The drug is designed to act like a natural brain protein (orexin) that helps keep people awake. Researchers will check if ORX750 is …
Matched conditions: NARCOLEPSY TYPE 1
Phase: PHASE2 • Sponsor: Centessa Pharmaceuticals (UK) Limited • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
Extended trial tests sleep disorder drug's long-term effects
Disease control Recruiting nowThis study continues testing the ORX750 medication for people with narcolepsy and idiopathic hypersomnia who completed an earlier trial. It aims to understand the long-term safety and effectiveness of the drug when taken over an extended period. The research will monitor side eff…
Matched conditions: NARCOLEPSY TYPE 1
Phase: PHASE2 • Sponsor: Centessa Pharmaceuticals (UK) Limited • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
Extended trial tests new sleep disorder medication
Disease control Recruiting nowThis study continues testing ALKS 2680 tablets for people with narcolepsy or idiopathic hypersomnia who completed earlier trials. Researchers want to see how safe the medication is over a longer period and whether its benefits last. Participants will take the tablets regularly to…
Matched conditions: NARCOLEPSY TYPE 1
Phase: PHASE2, PHASE3 • Sponsor: Alkermes, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
5-Year global trial tests Long-Term safety of promising narcolepsy drug
Disease control Recruiting nowThis study aims to check the long-term safety and side effects of the drug TAK-861 in people with type 1 narcolepsy. It will follow up to 500 participants for about 5 years to see how well they tolerate the medication over time. The study also tracks changes in key narcolepsy sym…
Matched conditions: NARCOLEPSY TYPE 1
Phase: PHASE2, PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Mar 13, 2026 15:06 UTC
-
Scientists investigate pain as early warning sign for Parkinson's disease
Knowledge-focused Recruiting nowThis study aims to understand pain perception in people with REM sleep behavior disorder (iRBD), a condition that often develops into Parkinson's disease years later. Researchers will compare pain experiences between 24 people with iRBD and a control group with narcolepsy. By mea…
Matched conditions: NARCOLEPSY TYPE 1
Phase: NA • Sponsor: University Hospital, Toulouse • Aim: Knowledge-focused
Last updated Apr 02, 2026 14:57 UTC
-
Spain launches major count of rare sleep disorder
Knowledge-focused Recruiting nowThis study aims to find out exactly how many people in Spain have narcolepsy, a rare sleep disorder causing severe daytime sleepiness. Researchers will review hospital records across the country to count diagnosed cases and track how many new cases appear each year. The goal is t…
Matched conditions: NARCOLEPSY TYPE 1
Sponsor: Takeda • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:17 UTC
-
Could your gut hold clues to narcolepsy?
Knowledge-focused Recruiting nowThis study aims to understand if changes in gut bacteria and a 'leaky gut' might be involved in causing type 1 narcolepsy, a serious sleep disorder. Researchers will compare 120 people with narcolepsy to healthy volunteers by analyzing their blood, stool, and spinal fluid. The go…
Matched conditions: NARCOLEPSY TYPE 1
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Mar 18, 2026 14:41 UTC